Connect with us

MARKETS

Amfil Technologies Inc (OTCMKTS:AMFE) Acquires Morning

Published

on

Amfil Technologies Inc (OTCMKTS:AMFE) has taken over Morning as announced in March 2018 for $150,000.

A group of young professionals is working hard at Morning, which is based in Toulouse, France, to develop and provide quality and innovative games. The company supplies the innovative games to the retailers in France.

Morning will unveil a number of games in the market. Some of the game titles that will hit the market shortly are Kill The Unicorns, Red Panda, and IKAN.

Kill The Unicorns

This game is developed to offer fun and enjoyment to casual gamers and families. It is developed based on the Unicorn Theme. It has the backing of finance from 8,000 and a number of partners.

Following the takeover, a group of six professionals from Snakes & Lattes Publishing SAS will manage Morning. Amfil Technologies will extend necessary support to promote published games. It will also distribute the games in other countries. Snakes & Lattes is planning for franchising and expansion in the US and Canada.

Amfil Technologies Issues an Update on Snakes & Lattes Inc

Amfil Technologies issues an update on Snakes & Lattes Inc.’s operations to the investing community and shareholders. The company will also give an update on the operations of Morning and provide details about an ongoing audit.

The operations of Snakes & Lattes consists of College and Annex locations based in Toronto, ON. The expansion team of Snakes & Lattes have already made considerable strides in improving the brand in the US.

The company is putting in considerable efforts to establish joint ventures and franchises in 23 locations across the US and is negotiating with interested parties. The company will finalize the franchise agreements after the announcement of audited results. It will depute an expansion team to each location to qualify the candidates and finalize the business plans. It will also provide an opportunity for the potential investors to meet the US expansion team.

Amfil Technologies has doubled its size in 2017. Its first US location will become online in just six weeks. It has also recently acquired Morning. It is continuing the rapid expansion of Snakes & Lattes.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

BetterLife Pharma Inc (OTCMKTS:PVOTF) Readies Interferon Alpha-2b To Clear Caronavirus From The Airways Of Patients

Published

on

BetterLife Pharma Inc (OTCMKTS:PVOTF) expects to publish results of the third-party study of the drug – Interferon Alpha-2b in the journal Frontiers of Immunology this Friday. The company has examined the effectiveness of Interferon Alpha-2b on seventy-seven Wuhan based patients infected with moderate to severe coronavirus during January 16 and February 20, 2020. According to the study, the drug can effectively clear the coronavirus from the airways of affected patients.

An unexplored and uncontrolled study is conducted on seventy-seven patients in Wuhan by administering arbidol (200 mg t.i.d.) or nebulized IFN-α2b (5 mU b.i.d.) or a combination of both. In the trial, temperature, serum cytokine levels, blood chemistry, cell counts, and blood oxygen saturation levels are recorded. Interferon Alpha-2b has effectively reduced coronavirus duration either with or without arbidol in the upper respiratory tract. Further investigation is required on IFN-α2b to treat COVID-19.

Should give priority for clinical trials of Interferon Alpha-2b

The study is featured in the Canadian national newspaper – Globe and Mail in its May 13, edition under the article title ‘Interferon emerges as a potential treatment for COVID-19’. A researcher at Toronto University Health Network – Dr. Eleanor Fish said the awareness about this drug to treat coronavirus is slow and should give priority for the clinical trials on a large scale.

Interferons to treat coronavirus infections

According to Fish, interferons provide the first line of defense against all the viruses. However, viruses like coronavirus have evolved to block the response of interferon. It necessitates the need for interferons to treat coronavirus infections.

The new drug of BetterLife Pharma overrides the inhibitory effects of COVID-19. Fish said that instead of developing a virus-specific antiviral every time, it is better to consider interferons for the treatment of viruses like coronavirus.

Interferons have already received the nod to treat viral infections several years back. It is now time to repropose them to treat moderate to severe virus infections. Therefore, a large clinical trial involving Interferon Alpha-2b on a cohort of patients further supports the research.

CEO of BetterLife Pharma, Ahmad Doroudian, said the company is pleased with the results of a recently concluded study in using Interferon Alpha-2b to treat COVID-19. The outcome supports BetterLife’s approach to treating coronavirus. Ahmad said he supports the view of Fish and further excited by the recent study results.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

MARKETS

CV Sciences Inc (OTCMKTS:CVSI) Navigates Market Storms

Published

on

Any company that faces the campaign of short sellers experiences hard times; especially the shareholders. In the recent months, CV Sciences Inc (OTCMKTS:CVSI) had a rough battle with the investors which badly bruised the share price. In an Aug. 30, 2018 press statement, the company gave an update to shareholders regarding the situation.

In the update, CV Sciences acknowledges the “malicious” intent of the short sellers. The company CEO, Joseph Dowling further explains that they are victims of “campaigns run by short sellers in order to depress our stock price, so they could make financial windfalls.”

Manipulations

The CEO further details that: “We are also aware that at least one such group has boasted on social media platforms about its financial returns since their release of misleading information regarding the Company’s patent prosecution and drug development efforts.”

In rebuttal, the CEO affirms that the company presents strong financial numbers and that this will go on in future. He adds that there is nothing different with the business model since it is solid. Joseph speaks out so strongly about the “manipulations” and offers his sympathy for the shareholders.

“We will continue to do everything in our control to bring this activity to a halt. In the months ahead, we look forward to reporting our operating results in this fast-growing industry and providing updates on our drug development efforts,” he says.

A product milestone for CV Sciences Inc (OTCMKTS:CVSI)

The run in with the short sellers did not dampen the company’s spirits. In under two weeks, the company announced a great milestone for one of its products. The PlusCBD Oil™ Gold Formula product line acquired the Generally Recognized as Safe (GRAS) status. The status implies successful performance on the safety front. Further, the GRAS status implies the U.S. Food and Drug Administration (FDA) approves of the production and supply of PlusCBD Oil™.

Such a status is important to product sales and consumer confidence in the company. Concurring with the assessment, the CEO says:

“We are committed to building consumer confidence and trust in the safety and quality of our products, supported by scientific evidence.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Tilray (TLRY) Joins Cannabis Sector’s Pause, Which Is Good News For People Who Missed Its July IPO

Published

on

With the high-flying cannabis sector taking a pause, now is the time for investors to reassess their positions.

A good place to start would be by taking a moment to examine who is guiding cannabis-focused companies. In other words, who is it that is forming a company’s reputation.

Take, for example, high-flying Tilray, Inc. (TLRY). It’s a pioneer in medical cannabis research, cultivation, processing, and distribution. Now it is rapidly staking a strong place in Canada’s soon-to-be legal adult marijuana market.

Looking beyond its world-class research teams, investors will discover Tilray has one of the sector’s most prestigious board of directors.

Tilray’s board includes Rebekah Doop, who is a principal at Google. Then there’s Scotty Greenwood, who was chief of staff sat the U.S. Embassy in Canada, and is now the CEO of the Canadian American Business Council.

Of course, the board itself is not solely responsible for the 400 percent run up since Tilray’s July IPO. Still, it should comfort investors to know Tilray is in such good hands.

Doop and Greenwood are joined on the board by other corporate heavyweights, such as Christine St. Claire, who was a principal and lead audit partner at KPMG; Michael Auerbach, a risk expert who has held senior positions at the Center for American Progress and The Century Foundation, where he concentrated on issues related to U.S. Foreign Policy, National Security, and Conflict Resolution.

Rapid Expansion Into Legalized Pot

Based in British Columbia, Canada, Tilray is global concern. It is the only GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments, and researchers in 11 countries on five continents.

It’s also perfectly positioned in the heart of Canada’s legalized cannabis industry.

The Prince Edward Island Cannabis Management Corporation recently selected a Tilray subsidiary to supply its adult-use cannabis.

The purchase order will allow its wholly owned affiliate, The High Park Company, to supply PEI’s four cannabis stores and online channels with cannabis products. It’s all in anticipation of the launch of the adult-use market on October 17, 2018.

In all, Tilray has signed agreements to supply adult-use cannabis to consumers in seven Canadian provinces and territories, including British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, the Yukon territory, and the Northwest Territories

Its subsidiary, High Park, is Toronto-based, and is led by a team with deep experience in cannabis and global consumer brands.

Tilray established High Park in order to develop, sell, and distribute a broad-based portfolio of adult-use cannabis brands and products. Its portfolio is uniquely crafted and grown by master horticulturists dedicated to sustainable growing practices.

Tilray’s shares were downgraded Northland Capital, which gave “complex valuations” as the basis of its esoteric reasoning. Tilray’s share price shed nearly 11 percent on the news.

But Tilray is a strong company.

It has a partnership to develop medical products with Sandoz Canada, a division of Novartis (NVS). Tilray also has a relationship with Privateer Holdings and marijuana information website Leafly, along with distribution deals with Shoppers Drug Mart, Pharmasave and various Canadian provinces.
It is perfectly posi

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories